Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study.
Br J Psychiatry
; 186: 222-6, 2005 Mar.
Article
em En
| MEDLINE
| ID: mdl-15738503
ABSTRACT
BACKGROUND:
Selective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice.AIMS:
To investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder.METHOD:
Patients with generalised social anxiety disorder were randomised to receive placebo (n=177) or 10-20 mg escitalopram (n=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score.RESULTS:
The study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P<0.01). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment.CONCLUSIONS:
Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Transtornos Fóbicos
/
Citalopram
/
Inibidores Seletivos de Recaptação de Serotonina
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article